ResMed Inc. (NYSE:RMD) Shares Sold by NN Investment Partners Holdings N.V.

NN Investment Partners Holdings N.V. trimmed its holdings in shares of ResMed Inc. (NYSE:RMD) by 20.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,367 shares of the medical equipment provider’s stock after selling 8,708 shares during the period. NN Investment Partners Holdings N.V.’s holdings in ResMed were worth $9,057,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. ST Germain D J Co. Inc. boosted its stake in ResMed by 0.3% in the 3rd quarter. ST Germain D J Co. Inc. now owns 14,637 shares of the medical equipment provider’s stock worth $3,858,000 after purchasing an additional 40 shares during the period. Allworth Financial LP grew its stake in shares of ResMed by 18.8% in the 3rd quarter. Allworth Financial LP now owns 297 shares of the medical equipment provider’s stock valued at $78,000 after buying an additional 47 shares in the last quarter. Clarius Group LLC increased its stake in shares of ResMed by 4.3% during the 3rd quarter. Clarius Group LLC now owns 1,172 shares of the medical equipment provider’s stock worth $309,000 after purchasing an additional 48 shares during the last quarter. JJJ Advisors Inc. raised its holdings in ResMed by 32.9% during the third quarter. JJJ Advisors Inc. now owns 194 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 48 shares in the last quarter. Finally, Advisory Services Network LLC raised its stake in shares of ResMed by 2.9% in the 2nd quarter. Advisory Services Network LLC now owns 1,746 shares of the medical equipment provider’s stock valued at $430,000 after acquiring an additional 50 shares in the last quarter. Institutional investors and hedge funds own 65.12% of the company’s stock.

A number of research analysts have recently commented on RMD shares. CLSA raised shares of ResMed from an “underperform” rating to an “outperform” rating in a research report on Friday, October 22nd. Robert W. Baird upgraded ResMed from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $270.00 to $300.00 in a research report on Thursday. Royal Bank of Canada increased their target price on shares of ResMed from $227.00 to $234.00 and gave the stock an “underperform” rating in a report on Thursday. Finally, Macquarie raised ResMed from a “neutral” rating to an “outperform” rating in a research note on Monday, December 6th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, ResMed currently has an average rating of “Hold” and an average price target of $260.50.

In other news, insider James Hollingshead sold 2,400 shares of the company’s stock in a transaction that occurred on Monday, November 1st. The shares were sold at an average price of $264.35, for a total transaction of $634,440.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Robert Andrew Douglas sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, November 15th. The shares were sold at an average price of $271.75, for a total transaction of $2,174,000.00. The disclosure for this sale can be found here. Insiders sold 39,691 shares of company stock worth $10,330,553 in the last ninety days. 1.42% of the stock is owned by company insiders.

RMD stock opened at $252.16 on Friday. The stock has a market cap of $36.74 billion, a price-to-earnings ratio of 73.95, a price-to-earnings-growth ratio of 2.54 and a beta of 0.30. The company has a fifty day moving average price of $256.40 and a two-hundred day moving average price of $264.70. ResMed Inc. has a one year low of $179.37 and a one year high of $301.34. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.54 and a quick ratio of 1.73.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 28th. The medical equipment provider reported $1.51 EPS for the quarter, topping the consensus estimate of $1.35 by $0.16. The business had revenue of $904.00 million during the quarter, compared to the consensus estimate of $858.20 million. ResMed had a net margin of 14.92% and a return on equity of 28.46%. ResMed’s revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.27 EPS. Research analysts anticipate that ResMed Inc. will post 6.26 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 16th. Stockholders of record on Thursday, November 11th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend was Tuesday, November 9th. ResMed’s payout ratio is 49.27%.

ResMed Profile

ResMed, Inc engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the following segments: Sleep and Respiratory Care, and Software as a Service.

Recommended Story: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.